Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.

Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, ...

Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive ...

Bristol-Myers Squibb stock has rebounded strongly ... I covered the approval of Cobenfy, following BMY's $14bn, 2023 acquisition of Karuna Therapeutics and Kar-XT, in a note shared with Seeking ...

With thousands of press releases published each week, it can be difficult to keep up with everything on. To help healthcare ...

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies. For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover ...

Trading at 8.12 times forward earnings, Bristol-Myers Squibb stock offers considerable value given its strong oncology franchise, acquisition strategy, and generous shareholder rewards.

It has been announced that following Bristol-Myers Squibb’s (BMS) successful acquisition of Amylin Pharmaceuticals, AstraZeneca (AZ) has made an initial payment of approximately US $3.2 billion ...